| Name | Sparfosic acid trisodium |
| Description | Sparfosic acid trisodium is a CAD (carbamoyl-phosphate synthetase 2) inhibitor and also an aspartate transcarbamoyl transferase inhibitor with antitumour activity. |
| In vitro | Method:
Br-1 and L-2 cell lines, established from metastases in nude mice injected with the human tumor cell line MDA-MB-435, were treated with Sparfosic acid trisodium (300 µM) for 12, 24, and 48 hours to evaluate its effects on the cell cycle.
Result:
Following treatment, both cell lines were predominantly arrested in the S phase, with a slightly higher proportion of S phase cells observed in L-2 compared to Br-1 cells. [1] |
| In vivo | Method:
Sparfosic acid trisodium was administered intraperitoneally at a dose of 490 mg/kg on days 1, 5, and 9 to tumor-bearing mice implanted with either B16 melanoma or Lewis lung carcinoma, to evaluate its antitumor efficacy.
Result:
In the B16 melanoma model, Sparfosic acid trisodium extended mouse survival by 77%–86% compared to controls. In the Lewis lung carcinoma model, the compound showed high sensitivity; subcutaneous administration on days 1, 5, and 9 Resulted in a 50% cure rate in tumor-bearing mice. [3] |
| Storage | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 160 mg/mL (577.41 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (18.04 mM), Sonication is recommended.
H2O : 200 mg/mL (721.76 mM), Sonication is recommended.
|
| Keywords | Sparfosic acid trisodium | Sparfosic acid |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
United States
